Contact Us

ELEVATING TOMORROW’S STANDARD OF CANCER CARE TODAY

 

WELCOME TO ABALYTICS ONCOLOGY

10 Million people die from cancer every year. It remains the cause of every sixth death. At Abalytics Oncology, our vision is to redefine the standard for drug development in the 21st century.

Contact Us

Core Values

How do you approach drug development in the age of artificial intelligence? Where do you choose to focus? At Abalytics Oncology, three simple values drive every action we take:

Overall survival

Quality of life

Greater Understanding

Strategic Missions for 2025 and Beyond

01

Develop best-in-class CTLA-4 targeting bispecific antibodies

02

Develop next-generation bispecific therapies with finely tuned dynamics

03

Build data model and system integrations to better treat immune dysregulation

Abalytics Stands for Antibody Data Analytics

Abalytics Intelligence

Sequences

Clinical Trials

Structures

Publications

Patents

Biomarkers

Companies

Technologies

Investments

Code

Real-world information, in real-time

Artificial Intelligence generates infinite options, which human intelligence evolved to constrain.

Abalytics Algorithms

Target selection

Antibody design

Lead identification

Translational modeling

Treatment optimization

Resource allocation

Abalytics Pipeline Programs

Bispecific oncology therapies

Bispecific immune cell modulators

Bispecific pMHC targeted TCR mimetics

We use computational antibody design and biomolecular engineering to develop better treatments

Bispecific Antibody Pipeline Programs

Program

Discovery

IND-Enabling Studies

Status

CTLA-4 targeting bispecific antibodies with unique dynamics

ABAO3

PD-1 / CTLA-4

Preclinical

ABAO4

CTLA-4 / XX

Preclinical

VEGF localizing tumor associated antigen targeting bispecific

ABAO5

VEGF / TAA

R&D

Bispecific cytokine and immune cell modulating antibody for autoimmune conditions

ABAO6

YY / ZZ

R&D

pMHC-targeted bispecific TCR mimetic

ABAO7

pMHC / CD3

R&D

Our understanding of antibody therapeutics continues to evolve, but molecular dynamics remain a black box

X

INPUT
(1017) molecules with an identical coded sequence are dosed in a human you love…
(1017) molecules with an identical coded sequence are dosed in a human you love…
INPUT

X

2nd+ order PD interactions

  • Blockade
  • Internalization
  • Recycling
  • Degradation
  • Protein-protein
  • Protein-cell
  • Cell-cell
  • …

Y = F(X)

OUTPUT
  • Objective Response
  • Treatment Related Adverse Events
  • Overall Survival

SEQUENCE

STRUCTURE

PATIENTS SPECIFIC OUTCOMES

DYNAMICS

With only the first prediction problem “solved”, how can we achieve the outcomes we want?

ABAO3: A next generation PD-1 / CTLA-4 bispecific antibody enhances safety and efficacy with PD-1 degradation and CTLA-4 recycling

Features

Opportunity

CTLA-4 Recycling

Minimize Toxicity

PD-1 Degradation

Maximize Efficiency

Validated Epitopes

Minimize Uncertainty

ABA03

PD-1 / CTLA-4 BsAb

  • Ipilimumab and Tremelimumab validate anti-CTLA4 development in solid tumors
  • Robust Overall Survival across tumor types limited by the severe immune related Adverse Events (irAE) of legacy approaches
  • Novel insights demonstrate the feasibility of delivering anti-CTLA4 efficacy without the toxicity

Abalytics Oncology next generation antibody-based pMHC targeted therapies aim to distinguish cancer from self

The information age has unlocked new insights into where cancer appears that we can target

Abalytics computational design offers advantages over existing TCR  and TCR mimetic approaches

Modular next-generation antibody-based formats offer validated options to optimize safety, efficacy, and developability

Our Team

Shay Paintal

Chief Executive Officer

Shay combines a track record of successful computational antibody design and development with a decade of experience founding data analytics ventures. He is credited with the invention of Omoprubart and has executed on over 20 other drug development programs, including TY027. Before formalizing a system for computational antibody design in the Sasisekharan Lab at MIT’s Koch Institute for Integrative Cancer Research, Shay spent a decade building technology solutions for public and private sector clients exploring practical applications of artificial intelligence. An ex-Deloitte Systems Integration consultant, Shay holds a Bachelor of Science in 
Read More

Manish Potti

Chief Business Officer

Manish has a track record of execution in the biopharmaceutical industry. He was the Chief Business Officer of Shinkei Therapeutics, a CNS focused company. He was previously the President and co-founder of Innogenix Pharmaceuticals. At Innogenix, Manish took a brownfield project through FDA facility approval, directed the R&D strategy, in-licensed assets, and grew the revenue to a stable base. He was also the head of business development of Epic Pharma, where he led the sale process of the company to Humanwell Healthcare of China in 2016. Since 2016, he has been actively investing and managing portfolio companies in health care
Read More

Joyson Karakunnel

Advisor: Strategic and Medical Affairs

Joyson Karakunnel is an experienced medical oncologist and hematologist with over 20 years of experience in drug development both in academia and industry in multiple therapeutic areas and drug modalities. He is an independent consultant for private and public biotechs and VC/PE firms. He serves on the BOD for Primevax and Precision Biologics. He has served as an advisor at the Parker Institute for Cancer immunotherapy. He was CMO at iTeos Therapeutics, Innate Pharma, Tizona Therapeutics and was part of the founding team for Trishula Therapeutics. He has held leadership positions at Arcus Biosciences and Medimmune/Astrazeneca where 
Read More

Toni Choueiri

Advisor: Scientific and Clinical

Dr. Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute, co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. He is the Medical Director, International Strategic Initiatives at Dana-Farber and past President of the Dana-Farber Medical Staff (2016-2018). Dr. Choueiri is an elected member of the American Society of Clinical Investigation (ASCI). In addition, he is an Aresty Scholar from the Wharton School of Business at the University of Pennsylvania. 
Read More

Sherry La Porte

Advisor: Antibody Engineering, Development, and Strategy

Sherry LaPorte is a biotech veteran with vast experience in antibody engineering and development. As Director of Biotherapeutics Engineering at Janssen, she led efforts in multi-specific antibody design and ADC development. At CytomX Therapeutics, she focused on masking technologies and advancing innovative antibody platforms, and at Pfizer, she contributed to the development of clinical candidates across oncology, immunology, and neurodegeneration. Earlier in her career, Sherry conducted postdoctoral research at Stanford and UCSF, where she focused on molecular biology and structural immunology, building a strong foundation for translating sequence-level insights into clinical-stage therapeutics.

Contact us

Connect with us about reshaping the future of cancer care today.

© 2024 Abalytics Oncology. ALL RIGHTS RESERVED

Facebook Instagram
Scroll to Top

Shay combines a track record of computational antibody design and development with a decade of experience implementing data analytics systems across diverse healthcare settings. He is credited with the invention of Omoprubart and has executed on over 15 other cutting edge drug development programs, including TY027. Before formalizing a system for computational antibody design in the Sasisekharan Lab at MIT’s Koch Institute for Integrative Cancer Research, Shay developed technology solutions for public and private sector clients exploring practical applications of artificial intelligence. An ex-Deloitte Systems Integration consultant, Shay holds a Bachelor of Science in Chemical and Biomolecular Engineering from Johns Hopkins University.

Manish has a track record of execution in the biopharmaceutical industry. He was the Chief Business Officer of Shinkei Therapeutics, a CNS focused company. He was previously the President and co-founder of Innogenix Pharmaceuticals. At Innogenix, Manish took a brownfield project through FDA facility approval, directed the R&D strategy, in-licensed assets, and grew the revenue to a stable base. He was also the head of business development of Epic Pharma, where he led the sale process of the company to Humanwell Healthcare of China in 2016. Since 2016, he has been actively investing and managing portfolio companies in health care. Manish has overseen R&D, regulatory, commercial, and manufacturing in his career. He began his career in banking and as a trader at a hedge fund. Manish holds a Bachelor of Science in Molecular Biology from Johns Hopkins University, and a Master’s in Financial Engineering from New York University.

 

Joyson Karakunnel is an experienced medical oncologist and hematologist with over 20 years of experience in drug development both in academia and industry in multiple therapeutic areas and drug modalities. He is an independent consultant for private and public biotechs and VC/PE firms. He serves on the BOD for Primevax and Precision Biologics. He has served as an advisor at the Parker Institute for Cancer immunotherapy. He was CMO at iTeos Therapeutics, Innate Pharma, Tizona Therapeutics and was part of the founding team for Trishula Therapeutics. He has held leadership positions at Arcus Biosciences and Medimmune/Astrazeneca where he was involved in the approval for Imfinzi and Imjudo in monotherapy and combination settings. Prior to joining the pharmaceutical industry, he was an investigator in clinical trials at the NCI and team leader for the hematologic group at Walter Reed National Military Medical Center. He was an Associate Professor at the Uniformed Services University of the Health Sciences and medical reviewer at the FDA. He did his fellowship training in hematology and oncology at the National Cancer Institute and residency training at Overlook Hospital/UMDNJ. He was elected as a Fellow in the American College of Physicians (FACP). He completed his medical training at Annamalai University in India. He holds a Master’s of Pharmacology from the University of Maryland and is a member of Phi Beta Kappa. he holds an MBA from the Kelley School of Business.

Dr. Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute, co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. He is the Medical Director, International Strategic Initiatives at Dana-Farber and past President of the Dana-Farber Medical Staff (2016-2018). Dr. Choueiri is an elected member of the American Society of Clinical Investigation (ASCI). In addition, he is an Aresty Scholar from the Wharton School of Business at the University of Pennsylvania. Dr. Choueiri is interested in developing novel experimental therapies and biomarkers in GU malignancies as well as interest in liquid biopsies and markers of toxicity of systemic agents. His work has been published in journals such as the NEJM, Nature, Nature Medicine, Science, Journal of American Medical Association (JAMA), JAMA Oncology, The Lancet, Lancet Oncology, and Journal of Clinical Oncology. He lectures frequently throughout the United States and around the world. He has over 800 PubMed-indexed publications and is the lead investigator of multiple national and international phase I-III trials in GU cancers.